CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Foundational Principles for the Quantitative Translation of T-Cell Therapeutics for Hematologic Malignancies and Immunology.
Foundational Principles for the Quantitative Translation of T-Cell Therapeutics for Hematologic Malignancies and Immunology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T细胞衔接抗体(TCE)和嵌合抗原受体(CAR)T细胞是精准医疗疗法,已革新血液系统恶性肿瘤的治疗。其肿瘤学领域的成功引发了将这一前景拓展至自身免疫性疾病等其他适应症的兴趣。本综述讨论机制建模的基础原则,旨在建立统一评估框架,支持跨治疗模式(CAR-T 与TCE)及跨适应症(肿瘤学与免疫学)的转化评估。该框架纳入各治疗模式的独特要素,如CAR-T 细胞动力学、TCE药代动力学及其与靶细胞形成复合物的过程;同时纳入不同适应症间共通的要素,如B细胞动力学和生物分布。我们阐述这种整合方法如何为免疫疗法的个体化、高效治疗策略提供循证决策依据。
T-cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR-T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders. This review discusses the foundational principles for mechanistic modeling to provide a unified assessment framework for cross-modality (i.
e. , CAR-T cells vs. TCEs) and cross-indication (i. e. , oncology vs. immunology) translation. This framework captures the unique elements of each modality, such as CAR-T cellular kinetics, TCE pharmacokinetics, and complex formation with target cells, as well as shared elements such as B-cell kinetics and biodistribution across indications.
We describe how this integrated approach can lead to informed decision making for more personalized and effective treatment strategies with these immune therapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。